Health, Human Rights and the Pharmaceutical Industry by Montgomery, Gerald
Human Rights & Human Welfare 
Volume 4 Issue 1 Article 33 
2004 
Health, Human Rights and the Pharmaceutical Industry 
Gerald Montgomery 
Follow this and additional works at: https://digitalcommons.du.edu/hrhw 
 Part of the Health Policy Commons, Human Rights Law Commons, International Law Commons, and 
the Pharmacy Administration, Policy and Regulation Commons 
Recommended Citation 
Montgomery, Gerald (2004) "Health, Human Rights and the Pharmaceutical Industry," Human Rights & 
Human Welfare: Vol. 4 : Iss. 1 , Article 33. 
Available at: https://digitalcommons.du.edu/hrhw/vol4/iss1/33 
This Topical Research Digest is brought to you for free and open access by the Josef Korbel School of International 
Studies at Digital Commons @ DU. It has been accepted for inclusion in Human Rights & Human Welfare by an 
authorized editor of Digital Commons @ DU. For more information, please contact jennifer.cox@du.edu,dig-
commons@du.edu. 
R E V I E W  D I G E S T :  H U M A N  R I G H T S  &  H E A L T H   
 112 
Health, Human Rights and the Pharmaceutical Industry  
by Gerald Montgomery 
 
PARAGRAPH 6 OF THE DOHA DECLARATION ON THE TRIPS AGREEMENT 
AND PUBLIC HEALTH, World Trade Organization, 2 September, 2003:  
We are committed to helping countries that are experiencing public health crises. We want to find a real 
solution to problems that prevent Members from being able to address health problems associated with access 
to pharmaceuticals. We want all Members to be able to use the full flexibility of the TRIPS Agreement to 
help provide their citizens access to affordable medicines in times of crises. 
We note that the Doha TRIPS declaration recognizes that the exclusive rights provided by patents are an 
important incentive to development of new drugs. Patents provide market incentives for innovators to risk 
time, energy and resources to develop and bring to market new technology. A system of patent rights and 
enforcement of those rights for pharmaceuticals provides numerous benefits to society; the availability of 
exclusive patent rights for pharmaceutical products spurs research and development of new medicines, including 
those resulting from biotechnology, to treat and cure diseases …. 
The pharmaceutical industry is a crucial touchstone in the discussion of corporate responsibility 
to promote human rights. This relationship is, however, problematic at best and, at worst work in 
opposition to each other. At the same time that drug producers are instrumental in promoting a 
basic level of human welfare, the outlook of major pharmaceutical corporations are mitigated by 
unfiltered lenses of profit. With hundreds of millions of dollars spent on research and development, 
patenting, and marketing, they understandably develop strategies for handling reoccurring costs. But 
should a morally responsible international community redirect these costs to the developing world 
or ask consumers in the global North to endure “artificially high” prices to offset gross inequalities? 
Alternatively, is there means to set reasonable prices based on the economic reality of each country?  
The broad overriding theme of the selection of texts below will be that TRIPS (Trade-Related 
Aspects of Intellectual Property Rights) has greatly affected the supply of drugs to the Third World. 
This is because, among other things, TRIPS is based on the idea that artists, entrepreneurs and 
inventors have a legal right to protect profits derived from their ideas. An important practical 
implication of this belief is that it forces competitors to adhere to strict manufacturing guidelines, 
greatly affecting global drug supply. TRIPS, then, is a legal framework that creates standards that 
protects these works.  
However in the Uruguay round of talks, TRIPS was seen as disproportionately bolstering the 
legal rights of Northern countries. Characteristic of this, in the Uruguay round of talks Southern 
states argued that TRIPS promotes the interests of drug manufacturing Northern countries. In an 
effort to mediate these inequalities other international organizations such as the World Health 
Organization recommend policies that ensure the availability of drugs at affordable prices in 
documents like the Doha Declaration. Reflecting the political tenor and policy consequences of 
these debates, this bibliography organizes itself according to the following categories: pharmaceutical 
patent issues, company relations with developing countries, research, country cases, TRIPS, general, 
and laws, initiative, and policy. 
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Chien, Colleen. 2003. “Cheap Drugs at What Price to Innovation: does the compulsory licensing of 
pharmaceuticals hurt innovation?.” Berkeley Technology Law Journal 18(3): 853-903 
<http://papers.ssrn.com/sol3/papers.cfm?abstract_id=486723.>  
Abstract: The patent system is built on the premise that patents provide an incentive for innovation by offering a 
limited monopoly to patentees. The inverse assumption that removing patent protection will hurt innovation has 
largely prevented the widespread use of compulsory licensing—the practice of allowing third parties to use patented 
inventions without patentee permission…. The author comments on the use of compulsory licensing to reduce the 
price of AIDS and other drugs for developing countries. I suggest that, based on past experience, compulsory 
licenses need not result in a decline in innovation and that this policy option for increasing access to medicines 
deserves greater exploration. 
De Silva, Allenson. 2002. Pharmaceutical Drugs & Health: a Critique. Colombo, Sri Lanka: Centre 
for Society & Religion. 
Granville, Brigitte. 2002. The Economics of Essential Medicines. Washington, DC : Royal Institute 
of International Affairs; distributed worldwide by the Brookings Institution.  
Leufkens H.G.M.; F.M. Haaijer-Ruskamp; and A. Bakker. 1995. The Future of Medicines in Health 
Care: Scenario Report (Commissioned by the Steering Committee on Future Health Scenarios; 
Scenario Committee on Medicine in Health Care; WHO Collaborating Center for Drugs Policy 
Studies). Boston: Kluwer Academic Publishers. 
McGregor, Alan. 1997. “Couterfeit Drugs Flood Developing World.” Lancet 350(909): 1690-1694.  
Pérez-Casas, Carmen and Emilia Herranz. 2001. “Pricing of Drugs and Donations: options for 
sustainable equity pricing.” Tropical Medicine & International Health 6(11): 960-965. 
Abstract: Effective medicines exist to treat or alleviate many diseases which predominate in the developing world 
and cause high mortality and morbidity rates. Price should not be an obstacle preventing access to these medicines. 
Increasingly, drug donations are required of drug companies, but these are often limited in time, place or use. 
Measures exist which are more sustainable and will have a greater positive impact on people’s health. Principally, 
these are encouraging generic competition; adopting into national legislation and implementing TRIPS safeguards 
to gain access to cheaper sources of drugs; differential pricing; creating high volume or high demand through global 
and regional procurement; and supporting the production of quality generic drugs by developing countries through 
voluntary licenses if needed, and facilitating technology transfer. 
Ratanawijitrasin, Sauwakon; Stephen B. Soumerai; and Krisantha Weerasuriya. 2001. “Do National 
Medicinal Drug Policies and Essential Drug Programs Improve Drug Use?” Social Science & 
Medicine 53(7): 831-844.  
Abstract: Conducts a critical review and synthesis of international literature in an attempt to define the state of 
knowledge regarding drug policy effects on drug use. Tests whether the development of national policies and 
regulations by the governments of developing countries increase the affordability, supply safety and rational use of 
pharmaceuticals. 
2
Human Rights & Human Welfare, Vol. 4 [2004], Iss. 1, Art. 33
https://digitalcommons.du.edu/hrhw/vol4/iss1/33
R E V I E W  D I G E S T :  H U M A N  R I G H T S  &  H E A L T H   
 114 
Stokes, Bruce. 2003. “It’s All About the Medicine.” National Journal 35(29): 2368-2370. 
This article presents an effort to dispel myths about the problems developing countries have in 
accessing low cost drugs. In doing so the article describes why the U.S. is deadlocked with the 
international community on important parts of the agenda of the upcoming Doha round of 
talks.  
Weissman R. 1999. “AIDS Drugs for Africa.” Multinational Monitor 20(September): 9-14. 
Documents the course of the dispute between the U.S. government and the South African 
government over providing affordable drugs to the poor. Interestingly, the article argues that 
South Africa and many other African nations are rendered politically and domestically unstable 
from high AIDS coupled with unaffordable drug therapies. The conclusion is that the laws and 
practices of major drug exporting countries such as the U.S. are used by pharmaceutical 
companies to profit at the expense of developing countries and their populations.  
Winestock, Geoff and Helene Cooper. 2001. “Activists Outmaneuver Drug Makers at WTO.” Wall 
Street Journal - Eastern Edition (November 14): A2. 
World Health Organization. 1999. Marketing Authorization of Pharmaceutical Products With 
Special Reference to Multisource (Generic) Products: a Manual for a Drug Regulatory Authority. 
Geneva: World Health Organization. 
 
Company Relations With Developing Countries 
 
“Drug Makers Hope to Profit From WTO Decision on Medications.” 2003. Health & Medicine 
Week (October 27): 331-334. 
Abstract: Reports on the efforts of the Brazil-based drug maker Cristalia Acquisition Corp. to try to profit from 
the World Trade Organization’s agreement allowing impoverished nations to import copied patented medicines to 
fight killer diseases. Benefits of the agreement for the company; Background of Cristalia; Criticism over the ability 
of Brazil to produce enough generic drugs for countries that need them. 
Global Partnerships: Humanitarian Programs of the Pharmaceutical Industry in Developing 
Nations. 2003. Washington, D.C.: Pharmaceutical Research and Manufacturers of America. < 
http://world.phrma.org/global.partnership.2003.pdf.> 
“Pharmaceutical Company Honored With First Ever Pro Bono Partner Award.” 2003. Biotech Week: 
14. 
This article highlights the growing number of U.S. pharmaceutical companies that perform pro 
bono work fusing the talents of public and private enterprises. Reports on the presentation of 
CorporateProBono.Org’s (CPBO) Pro Bono Partner Award to Abbott Laboratories (ABT) Inc. 
recognizing its work with Baker and McKenzie and the Midwest Immigrant and Human Rights 
Center to provide legal counseling to immigrants and career counseling to high school students. 
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“Pilot Program Launched to Expand Access to Medicines in Poorest Countries.” 2003. AIDS 
Weekly (February 17): 16-18. 
Reports on the launch of a pilot program for expanding access to needed medicines for AIDS-
infected people in developing countries by Pharmacia Corp. Also highlights the partnership of 
the company with International Dispensary Association Foundation to grant non-exclusive 
licenses to generic pharmaceutical companies for AIDS drug Delavirdine.  
“Progress Reported in Cutting AIDS Drug Prices for Poor Nations.” 2003. AIDS Weekly (February 
17): 35-37. 
Reports on the progress made by global business leaders in making cheaper AIDS drugs 
available in developing countries. Information covered includes a grant announcement by 
founder of Microsoft Corp. Bill Gates, for funding such medical researches in developing 
countries; concerns of the U.S. pharmaceutical companies over the protection of drug patents in 
these nations; reason why charitable institutions have to work really hard in developing 
countries. 
Agrawal, Madhu. 1999. Global Competitiveness in the Pharmaceutical Industry: the  
Effect of National Regulatory, Economic, and Market Factors. New York: Haworth Press. 
Bale, Harvey E. “Are International Pharmaceutical Companies Doing Enough to Provide Low-Cost 
AIDS Drugs to Developing Countries?” International Debates 1(4): 108-113. 
Presents the author’s views in favor of international pharmaceutical companies’ steps in 
providing low-cost AIDS drugs in developing countries. Role of pharmaceutical company in 
developing effective drugs to prevent the disease; Pricing policy followed by pharmaceutical 
company while subsidizing drugs for AIDS. 
Brugha, Ruairi. 2003. “Antiretroviral Treatment in Developing Countries: the Peril of Neglecting 
Private Providers.” British Medical Journal; International Edition 326(7403): 1382. 
Abstract: Increased access to antiretroviral drugs is vital to maintain developing countries with high rates of 
HIV infection. But unless treatment is properly controlled, these drugs could rapidly become useless. 
Note: The increasing problem of delivering antiretroviral drugs being handed out in poorer 
countries is the increased likelihood of the indiscriminate use could lead leading to increased to 
resistance if drug resistance if the supply and usage s are not regulated. The article includes 
several case studies from Africa (Uganda and Senegal) and identifies methods (such as working 
with the private sector) to alleviate this problem. 
Carpenter, Dave. 2003. “Do-Good Pharmas?” Hospitals & Health Networks 77(10): 48-51. 
Provides a discussion of Pfizer as an example of how a company can bridge the gap between 
profit margins and social responsibility in providing access to health care in developing 
countries. 
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Cohen, Jillian Clare. 2001. Pharmaceutical Napsters?: a Comparative Study of State Response to the 
Pharmaceutical Imperatives on the agreement on Trade-Related Aspects if Intellectual Property 
Rights. Ann Arbor, MI: University of Michigan Press.  
Dugger, Celia W. 2001. “A Catch-22 on Drugs for the World’s Poor; The Right to make generics, 
but not the means to do it.” New York Times (November 16): W1.  
A discussion of the inability of poor countries to manufacture low cost drugs, but do not have 
the means to do so and are not allowed to import them from countries that do so. 
Fleck, Fiona. 2003. “No Deal in Sight on Cheap Drugs for Poor Countries.” British Medical Journal; 
International Edition 326(7387): 465.  
Notes: This article describes trade negotiations held for the purpose of hammering out an 
agreement on the importation or creation of cheap drugs for the developing world. The United 
States’ blocked agreements to allow third world countries the right to produce low cost drugs 
because of concern over patent and intellectual property issues.  
Ford, Nathan. 2003. “Public Health and Company Wealth: When Public Protest at the Price of 
AIDS Drugs Reached a Peak, Pharmaceutical Companies Seemed to Take Note, but the 
Developing World’s Health Problems Will Never Really Be Tackled As Long As Remedies for 
Western Afflictions Remain More Profitable.” British Medical Journal; International Edition 
326(7402): 1296. 
This editorial reviews the availability and pricing of drugs in third world countries with those of 
the developed world. Argues that countries are responsible for ensuring health care and 
companies supplying drugs need to do take a more responsible role as a partner in the fight 
against massive endemics such as aids. 
Goodman, Sally. 2003. “Poor Nations Push for Right to Produce Cheap Medicines.” Nature 
411(6841): 982-986. 
Reports that developing countries have requested the modification of the global trading rules on 
the distribution of medicines at the June 20, 2001 meeting of the World Trade Organization in 
Geneva, Switzerland. Also covers the aim of trade-related aspects of intellectual property rights; 
reaction of the United States delegates to the request. 
Knodro, Wayne. 2003. “Canada Delays Legislation on Cheap Drugs.” Lancet 362(9397): 1729. 
Abstract: This article focuses on how developing countries hoping to obtain cheap drugs from Canada to treat 
AIDS, tuberculosis, malaria, and other diseases will have to wait longer than expected for access to cheap drugs 
as internal debates have indefinitely delayed passage of the necessary legislation. Although the governing Liberal 
party tabled legislation on cheap drugs for poor countries on Nov 6—weeks later than promised—it promptly 
prorogued Parliament, dispatching the bill to death on the order paper, where it will have to be revived by the 
Prime Minister-in-waiting—Paul Martin–after he assumes office. 
Mattias Ganslandt; Keith E. Maskus; and Eina V. Wong. 2001. Developing and Distributing 
Essential Medicines to Poor Countries: the DEFEND Proposal. Stockholm, Sweden: IUI, the 
Research Institute of Industrial Economics <http://www.iui.se/wp/wp552/iuiwp552.pdf>. 
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Mytelka, Lynn Krieger. 1999. Competition, Innovation and Competitiveness in Developing 
Countries. Paris: Development Centre, Organisation for Economic Co-operation and 
Development.  
Nullis, Clare. “Agreement on Access to Cheap Medicines Remains Elusive.” 2002. Associated Press 
Dec. 12.  
Silversides, Ann. 2003. “No Turning Back on Cheap AIDS Drugs for Poor Nations, U.N. Vows.” 
CMAJ: Canadian Medical Association Journal 169(10): 1067. 
Canada is trying to take the lead in changing drug patents for the purpose of exporting cheaper 
drugs to developing countries with the hope that other wealthy countries will follow suit. 
Thurow, Roger and Scott Miller. 2003. “Empty Shelves: As U.S. Balks on Medicine Deal, African 
Patients Feel the Pain --- Big Drug Makers, Protecting Their Patents, Seek Limits To a Global 
Trade Accord --- Searching for Insulin in Chad.” Wall Street Journal - Eastern Edition (June 2): A1. 
Vastag, Brian. 2003. “Alarm Sounded on Fake, Tainted Drugs: Some Wholesalers Are a Weak Link 
in a Dangerous Chain.” Journal of the American Medical Association 290(8): 1015-1017. 
Weissman, Robert. 1999. “AIDS Drugs for Africa.” Multinational Monitor 20(9): 9-14.  
Documents the course of the dispute between the U.S. government and the South African 
government over providing affordable drugs to the poor. Interestingly, the article argues that 
South Africa and many other African nations are rendered politically and domestically unstable 
from high AIDS coupled with unaffordable drug therapies. The conclusion is that the laws and 
practices of major drug exporting countries such as the U.S. are used by pharmaceutical 
companies to profit at the expense of developing countries and their populations. 
 
Country Cases 
NA. 2004. “HIV Treatment As a Human Right - Learning From Thailand’s Experience.” Biotech 
Week (March 3): 157. 
Abstract: A new paper discusses the landmark legal case in Thailand where two people with HIV infections 
successfully challenged a multinational pharmaceutical company for restricting access to a key antiretroviral drug 
due to its high cost. Nathan Ford and colleagues from the organization Medecins Sans Frontieres, authors of the 
viewpoint article which appeared in the journal “Lancet” discussed the processes behind this case and the 
implications for drug access as a human rights issue in other developing countries.  
Acharya, Rohini. The Emergence and Growth of Biotechnology Experiences in Industrialized and 
Developing Countries. Cheltenham, UK; Northampton, Mass. E. Elgar, 1999.  
Chaudhuri, Shubham; Pinelopi Koujianou Goldberg; and Panle Jia. 2003. The Effects of Extending 
Intellectual Property Rights Protection to Developing Countries: a Case Study of the Indian 
Pharmaceutical Market. Cambridge, MA: National Bureau of Economic Research.  
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Patel, Vikram; and Chittaranjan Andrade. 2003. “Pharmacological Treatment of Severe Psychiatric 
Disorders in the Developing World: Lessons From India.” CNS Drugs 17(15): 1071-1081. 
Discusses the various cultural, biological, and availability issues pertaining to drug treatment in 
areas of the world that do not have high incidences of mental disorders. Also comments on the 
costs and treatment options in different regions of the world. 
Thomas, L. G., III. 2001. The Japanese Pharmaceutical Industry: the New Drug Lag and the  
Failure of Industrial Policy. Northampton, MA: Edward Elgar. 
 
Laws, Initiative, Policy  
“New WTO’s Policy to Protect Public Health Interests for Developing Countries. “ 2003. Asia-
Pacific Biotech News 7(22): 1452. 
“WTO Panel Delays Decision on Cheap Drugs for Poor Countries.” 2003. Drug Week (September 
26): 157-158.  
Reports on the decision of the World Trade Organization (WTO) to delay a measure which will 
give poor nations access to inexpensive generic drugs. Addresses the impact of the move on 
poor nations; provides an overview of WTO rules regarding drug importation; and raises 
concerns of U.S. pharmaceutical industries over drug smuggling.  
Jacobzone, Stephane. 2000. Pharmaceutical Policies in OECD Countries: Reconciling Social  
and Industrial Goals. Paris, France: Organisation for Economic Co-operation and Development. 
Kapp, Clare. 2003. “World Trade Organisation Reaches Agreement on Generic Medicines: New 
Deal Will Make It Easier for Poorer Countries to Import Cut-Price Generic Drugs Made Under 
Compulsory Licensing.” Lancet 362(9386): 807. 
Reports on an agreement within the World Trade Organization (WTO) which allows developing 
countries stricken with HIV/AIDS, tuberculosis, and malaria to import cheap generic drugs. 
The centerpiece of the agreement which concerned the waiver of the normal rule that 
production of cheap generic drugs without the consent of the patent holder---compulsory 
licensing--must be primarily for the domestic market; Resolution of the issue which ended a long 
stalemate; Reactions from representatives of Africa, Brazil and other countries. 
Loff, Bebe. 2002. “World Trade Organzation Wrestles With Access to Cheap Drugs Solution.” 
Lancet 360(9346): 1670. 
Reports on the World Trade Organization (WTO) meeting in Sydney, Australia to resolve how 
poor nations can access cheap drugs. Meeting focusing on the agreement on Trade Related 
Aspects of Intellectual Property Rights (TRIPS) governing domestic patent law and how it 
influences access to pharmaceuticals; how the WTO softened trips stating that in cases of 
epidemics it is permissible for governments to grant a compulsory license to manufacture drugs 
still under patent. 
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Moran, Alan. 2003. “Trade Laws and Pharmaceuticals.” IPA Review 53(4): 25-28.  
Abstract: Focuses on trade aspects of intellectual property rights and provides a history of property rights. Also 
addresses manufacturing and administrative costs for a vaccine as well as features of modern commerce and law 
that prevent goods from being supplied more cheaply to developing countries. 
Moran, Mary and Nathan Ford. 2003. “The G8 and Access to Medicines: No More Broken 
Promises.” Lancet 361(9369): 1578. 
Provides a detailed timeline of the previous conferences held by the G8 and their focus on the 
affordable drugs to developing countries while looking forward to the upcoming G8 conference 
in France. 
Oxfam GB. 2001. Cut the Cost: Patent Injustice: How World Trade Rules Threaten the Health of 
Poor People. Oxford: Oxfam. 
http://www.oxfam.org.uk/what_we_do/issues/health/downloads/patentinjustice.pdf 
Pfizer Inc. 2003. “Bringing Treatments, Developing Cures.” The Pfizer Journal: Perspectives on Health 
Care and Biomedical Research. New York: Impact Communications.  
Pollock, Allyson M. and David Price. 2003.”New Deal From the World Trade Organization May 
Not Provide Essential Medicines for Poor Countries.” British Medical Journal; International Edition 
327 (7415): 571-573. 
Winestock, Geoff; and Helene Cooper. 2001. “Activists Outmaneuver Drug Makers at WTO.” Wall 
Street Journal - Eastern Edition 238(96): A2. 
World Health Organization. 1999. Marketing Authorization of Pharmaceutical Products With 
Special Reference to Multisource (Generic) Products: a Manual for a Drug Regulatory Authority. 
Geneva: World Health Organization. <http://www.who.int/medicines/library/qsm/manual-
on-marketing/multisource-contents.html>. 
 
Pharmaceutical Patent Issues 
“Institute for Oneworld Health Licenses Potent Therapy.” 2003. Drug Week (August 1).  
This article reports that the pharmaceutical company Oneworld Health has licensed a novel class 
of high-potency chemical compounds that may result in medicines for developing countries.  
“Patents and HIV/AIDS Drugs.” International Debates 1(4): 104. 
Abstract: Presents information about patent rights of manufacturing drugs to prevent HIV infection and AIDS 
disease. Gives criteria of granting patent to a particular pharmaceutical company; factors determining the access to 
essential drugs including drugs to treat HIV and other infections; and risk of HIV infection and AIDS in 
developing countries. 
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Correa, Carlos María. 2000. Integrating Public Health Concerns into Patent Legislation in 
Developing Countries. Geneva: South Centre.  
Cullet, Phillipe. 2003. “Patents and Medicines: the Relationship Between TRIPS and the Human 
Right to Health. “ International Affairs 79(1): 139-60. 
Interrogates the dilemma of the human right to health versus the idea of intellectual property 
rights defined in TRIPS. It addresses the problem of how patents stand in the way of access to 
drugs and gives solutions on what can be done to alleviate the disparity.  
Cunningham, Ralph. 2003. “Health Crises Undermine Patent Rules.” Managing Intellectual Property 
130: 43-50. 
Abstract: Global patent issue -- ability of sick in developing countries to obtain patented medicines -- rights 
under threat -- any relaxing of rules by WTO or TRIPs could result in fewer patents -- new legislation in Asian 
countries -- new court takes over -- legislative tweaking -- effect of new laws in Pakistan unknown -- PCT 
possibilities.  
Vass, Alex. “WTO Relaxes Rule on Drug Patents.” British Medical Journal International Edition 
323(7322):1146. 
Abstract: International trade rules amount to institutional fraud and are preventing development in poor 
countries, says a report published this week by a leading charity. Whereas trade has been one of the most powerful 
driving forces in increasing prosperity for much of the world, millions of the world’s poor are being left behind, and 
there is a widening of inequalities between the rich and poor. International trade rules, says the Oxfam report, are 
“rigged in favour of the rich.” When developing countries export to rich country markets, they face tariff barriers 
that are four times higher than those faced by rich countries. These barriers cost them $100bn (£70bn; 113bn) a 
year, twice as much as they receive in aid. The report calls for an end to the universal application of the intellectual 




“Phase II Trial With PRO 2000 to Prevent HIV Transmission Begins in Africa. “ 2003. Biotech Week 
(July 16): 7. 
Abstract: Indevus Pharmaceuticals, Inc., (IDEV) announced the initiation of a phase II clinical trial in Africa 
assessing the safety of PRO 2000, a topically administered, vaginal microbicide designed to prevent infection by 
the human immunodeficiency virus (HIV) that causes AIDS. This trial will provide safety data for PRO 2000 
in a sexually active, developing country population, and PRO 2000 may be investigated in such African 
populations in expanded phase III testing in the future,” said Dr. Bobby Sandage, executive vice president, 
research and development at Indevus. Findings will build upon the growing clinical database for the drug.  
“Study: Generic Drugs Helping AIDS Fight.” 2003. Health & Medicine Week (October 13): 627-
628. 
Presents a report released by Doctors Without Borders on the use of generic drugs to treat 
AIDS patients in developing countries. Citation of competition between generic and branded 
9
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retroviral drugs; failure of most countries in meeting the goal of fighting and reversing the 
epidemics; problem f discrimination of HIV-positive persons. 
Bourinbaiar, Aldar S. and Vichai Jirathitikal. 2003. “Low-Cost Anti-HIV Compounds: Potential 
Application for AIDS Therapy in Developing Countries.” Current Pharmaceutical Design 9(18): 
1419-1432. 
Abstract: Considerable progress has been made in recent years in the field of drug development against HIV. 
However, the current cost of AIDS drugs is the main obstacle preventing their use in developing countries, where 
95% of HIV infected patients reside. The average yearly price of AIDS therapy and related health care of 
affected patients in the USA runs as high as $22,000...Even in the USA, patients without medical insurance 
cannot afford the costly therapy. …This review summarizes the development and discovery of affordable and 
potentially promising AIDS drugs.  
Kettler, Hannah and Adrian Towse. 2002. Public Private Partnerships for Research and 
Development: Medicines and Vaccines for Diseases of Poverty. London: OHE. 
Lang, Trudie and Brian Greenwood. 2003. “The Development of Lapdap, an Affordable New 
Treatment for Malaria.” Lancet Infectious Diseases 3(3): 162-168. 
Abstract: There is much discussion on how new drugs can be developed for use in developing countries at a price 
that makes them accessible to those who need them most… The partnership comprised between GlaxoSmithKline 





Abbott, Frederick M. 2002. WTO TRIPS Agreement and Its Implications for Access to 
Medicines in Developing Countries. London: Commission on Intellectual Property Rights. 
<http://www.iprcommission.org/papers/pdfs/study_papers/sp2a_abbott_study.pdf>. 
Bale, H.E. 2000. TRIPS, Pharmaceuticals, and Developing Countries: Implications for Drug Access 
and Drug Development. Geneva, Switzerland: International Federation of Pharmaceutical 
Manufacturers Association.  
Cullet, Phillipe. 2003. “Patents and Medicines: the Relationship Between TRIPS and the Human 
Right to Health.” International Affairs 79(1): 139-60. 
Abstract: Interrogates the dilemma of the human right to health versus the idea of intellectual property rights 
defined in TRIPS. It addresses the problem of how patents stand in the way of access to drugs and gives solutions 
on what can be done to alleviate the disparity. Access to drugs in developing countries is at present largely 
influenced by the TRIPS Agreement. TRIPS compliance in the field of health requires substantial changes to 
existing patent laws in some countries. These changes must be analyzed in the context of the spread of epidemics 
like HIV/AIDS and in relation to other international obligations that states have, for instance, with regard to 
the human right to health. Intellectual property rights treaties today have significant impacts on the realization of 
some human rights like the right to health. Also examined are these issues from the point of view of human rights 
10
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considering, in particular, the ways in which the relationship between human rights and intellectual property can be 
improved in international law.  
Lanoszka, Anna. 2003. “The Global Politics of Intellectual Property Rights and Pharmaceutical 
Drug Policies in Developing Countries.” International Political Science Review 24: 181-198. 
Abstract: One of the major characteristics of the emerging international economic order is the treatment of 
intellectual property rights (IPRS). Developing country members are very concerned about the impact that the 
World Trade Organization (WTO) Agreement on Trade-Related Aspects of Intellectual Property Rights 
(TRIPS) will have on their economies. TRIPS emphasizes a property rights approach whereby private “owners” 
of the inventions can restrict access on the basis of commercial considerations. As a consequence, higher prices for 
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incentives are largely externalized to the rest of the developing world. The WTO TRIPS agreement held out some 
promise of overcoming part of this problem, but just as the obligations of developing nations under TRIPS were 
beginning to take hold, the Doha ministerial declaration casts great doubt on the future credibility of patent rights 
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